Morgan Stanley has launched a new intellectual property securitisation in the latest sign of life for structured products and a revival of investor interest in even the most cutting-edge corners of the market.

The bank has launched a $250m deal for Vertex Pharmaceuticals, a US biotech company that would see investors repaid from contractual milestone payments on a drug still in development.